| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 13.13 mm | 13.13 mm | 13.13 mm | 13.13 mm | 13.13 mm | 13.13 mm |
| Cash burn (monthly) | 284.67 k | (no burn) | 3.40 mm | 3.93 mm | 2.36 mm | 2.90 mm |
| Cash used (since last report) | 801.56 k | n/a | 9.56 mm | 11.08 mm | 6.66 mm | 8.16 mm |
| Cash remaining | 12.33 mm | n/a | 3.57 mm | 2.05 mm | 6.47 mm | 4.96 mm |
| Runway (months of cash) | 43.3 | n/a | 1.1 | 0.5 | 2.7 | 1.7 |
| 13F holders | Current |
|---|---|
| Total holders | 45 |
| Opened positions | 5 |
| Closed positions | 11 |
| Increased positions | 7 |
| Reduced positions | 9 |
| 13F shares | Current |
|---|---|
| Total value | 13.20 bn |
| Total shares | 26.96 mm |
| Total puts | 1.70 k |
| Total calls | 2.80 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| Yair Chaim Schindel | 7.39 mm | $20.92 mm |
| Biotechnology Value Fund L P | 3.83 mm | $0.00 |
| BVF | 3.61 mm | $5.10 bn |
| LVP Life Science Ventures Iii | 3.12 mm | $0.00 |
| Forward Ventures V | 2.66 mm | $9.73 mm |
| Citadel Advisors | 1.52 mm | $2.14 bn |
| Vanguard | 1.15 mm | $1.62 bn |
| Laurion Capital Management | 698.00 k | $984.18 mm |
| Samsara BioCapital | 689.71 k | $972.49 mm |
| BLK BlackRock | 460.24 k | $648.93 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Nov 24 | Pomerantz Roger | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,034 | 0.00 | 126,478 |
| 25 Nov 24 | Pomerantz Roger | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,034 | 0.00 | 18,069 |
| 25 Nov 24 | Royston Ivor | Common Stock | Option exercise | Acquire M | No | No | 0 | 25,219 | 0.00 | 839,741 |
| 25 Nov 24 | Royston Ivor | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 25,219 | 0.00 | 50,438 |
| 25 Aug 24 | Pomerantz Roger | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,034 | 0.00 | 117,444 |
| 25 Aug 24 | Pomerantz Roger | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,034 | 0.00 | 27,103 |
| 25 Aug 24 | Royston Ivor | Common Stock | Option exercise | Acquire M | No | No | 0 | 25,219 | 0.00 | 814,522 |
| 25 Aug 24 | Royston Ivor | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 25,219 | 0.00 | 75,657 |
| 20 Jun 24 | Darcy Thomas E | Stock Option Common Stock | Grant | Acquire A | No | No | 0.569 | 50,000 | 28.45 k | 50,000 |
